Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Second-Line Therapy for Metastatic Pancreatic Adenocarcinoma

Grants and Contracts Details

StatusFinished
Effective start/end date12/15/216/7/24

Funding

  • Exelixis Inc.: $166,708.00